# Bone Biologics Corp

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Bone Biologics Corp).

## Overview

Bone Biologics Corp is a U.S.-based clinical-stage medical device company focused on bone regeneration for spinal fusion procedures. Its core technology is NELL-1, a recombinant human protein licensed exclusively from UCLA Technology Development Group and combined with demineralized bone matrix (DBM) to create the NB1 bone graft device. The company’s development program is centered on improving bone growth and fusion outcomes while avoiding the need for autograft harvest from a patient’s hip. Bone Biologics has not yet commercialized its lead product and is pursuing FDA approval through the premarket approval pathway for a combination device/drug product.

## Products & services

• NB1 bone graft device (NELL-1 + DBM)
• NELL-1 recombinant protein platform
• Spinal fusion bone regeneration product development
• Preclinical and clinical development services for bone repair

- **Lead bone graft device** (0%) — NB1 combines NELL-1 with DBM to support targeted bone regeneration in spinal fusion.
- **Recombinant protein platform** (0%) — NELL-1 is the underlying biologic technology used to stimulate bone formation.
- **Clinical development program** (0%) — Preclinical and human studies aimed at proving safety and effectiveness for FDA approval.
- **Licensed intellectual property** (0%) — Exclusive worldwide rights to UCLA-licensed NELL-1 patents and know-how.

- NB1 bone graft device for spinal fusion
- NELL-1 recombinant human protein technology
- NELL-1 combined with demineralized bone matrix (DBM)
- Bone regeneration solutions for orthopedic surgery
- Clinical-stage development of target-specific bone growth products
- Licensed intellectual property for NELL-1 worldwide applications

## Customers

Bone Biologics’ eventual customers are primarily spine surgeons and the hospitals or surgical centers that use bone graft products in spinal fusion procedures. The end patient population includes adults with degenerative disc disease, spondylolisthesis, retrolisthesis, and other spinal conditions that require fusion surgery. The company also depends on healthcare providers and third-party payors because they influence product adoption, reimbursement, and clinical use after approval. Until commercialization, its direct customer base is limited, and the business is still focused on generating clinical evidence that would persuade surgeons and payors to adopt NB1 over autograft or other biologics.

- **Spine surgeons** (primary) — They would use NB1 in lumbar spinal fusion to improve bone growth and avoid autograft harvest.
- **Hospitals and surgical centers** (primary) — They would purchase or stock the product for fusion procedures if it gains approval and surgeon adoption.
- **Patients with spinal degenerative disease** (primary) — They are the clinical beneficiaries of the product, especially those undergoing transforaminal lumbar interbody fusion.
- **Third-party payors** (secondary) — They affect reimbursement and therefore the commercial viability of any approved product.

- Spine surgeons choosing graft materials for lumbar fusion
- Hospitals and ambulatory surgical centers performing fusion procedures
- Patients with degenerative disc disease and related spinal conditions
- Third-party payors that influence reimbursement and adoption
- Healthcare providers seeking to avoid autograft harvest morbidity

## Geography

Bone Biologics is headquartered in the United States and is organized as a Delaware corporation with operations tied to U.S. regulatory and intellectual property systems. Its lead clinical study is being conducted in Australia, which gives the company an international development footprint even though commercialization is expected to depend heavily on U.S. FDA approval. The company’s technology license is described as worldwide, so the long-term opportunity is not limited to one geography. In practice, however, the business is still concentrated in the U.S. regulatory environment and in clinical development markets where spinal fusion trials can be run.

- United States is the core corporate and regulatory base
- FDA approval is required for U.S. commercialization
- Pilot clinical study is being conducted in Australia
- Worldwide license rights support future non-U.S. expansion
- Delaware incorporation and U.S. patent filings anchor the business

## Strategy

The company’s strategy is to advance NELL-1/DBM through clinical development and obtain FDA approval for spinal fusion use. It is positioning NB1 as a target-specific bone regeneration product with a safety and efficacy profile intended to compete with autograft, the current benchmark in spine fusion. A key part of the strategy is building clinical evidence through a multicenter pilot study and then progressing toward a pivotal U.S. trial. The company also relies on its exclusive UCLA license and patent portfolio to protect the technology and create barriers to entry.

- **Complete clinical development for NB1** (short-term) — Regulatory approval is the main gating factor before any commercialization can begin.
- **Secure FDA PMA pathway approval** (medium-term) — The company has been told the product will be regulated as a combination product requiring PMA in the U.S.
- **Protect and extend intellectual property** (medium-term) — Exclusive patents and licenses are central to competitive differentiation and future partnering value.

- Advance NB1 through clinical trials toward FDA PMA approval
- Use spinal fusion as the initial commercial indication
- Differentiate with target-specific bone regeneration versus autograft
- Leverage exclusive UCLA-licensed NELL-1 intellectual property
- Expand potential use into broader orthopedic and surgical specialties
- Build evidence on safety, fusion success, pain, and function outcomes

## Risks

Bone Biologics faces the typical risks of a clinical-stage medtech company: regulatory delay, clinical trial failure, and uncertainty over whether the product will demonstrate sufficient safety and effectiveness for approval. Because NB1 is expected to require a PMA, the approval process is longer and more demanding than for many device products, and any setback could materially delay commercialization. The company also depends on a small management team and on third-party manufacturing and supply inputs, which increases execution risk. More broadly, it competes against large orthopedic and med-tech companies with greater resources, and its future market access will depend on surgeon adoption, reimbursement, and compliance with healthcare fraud, privacy, and other regulations.

- **Regulatory approval risk** [critical] — NB1 is expected to require FDA PMA approval before U.S. commercialization, which is time-consuming and uncertain.
- **Clinical trial execution risk** [high] — The company is still generating evidence in pilot studies, and adverse results could stop or delay development.
- **Competitive pressure** [high] — Large orthopedic and med-tech companies may launch better-funded or faster-approved alternatives.
- **Key person dependence** [medium] — The company states it is heavily dependent on its CEO and CFO, making turnover disruptive.
- **Supply chain and manufacturing dependence** [medium] — Third parties provide raw materials and product components, which can constrain trials and future supply.
- **Healthcare compliance and privacy** [medium] — Anti-kickback, HIPAA, and related laws can restrict commercialization and create liability.

- FDA PMA approval risk for a device/drug combination product
- Clinical trial failure or delay in spinal fusion studies
- Competition from larger orthopedic and biologics companies
- Dependence on key executives and a small operating team
- Supply chain reliance on third-party manufacturers and raw materials
- Reimbursement and surgeon adoption risk after approval
- Healthcare compliance, privacy, and anti-kickback exposure

## Accounting

Bone Biologics is a pre-revenue clinical-stage company, so its financial statements are dominated by development spending, financing activity, and judgmental estimates rather than product revenue recognition. The most important accounting estimates include stock option and warrant valuation and the assessment of income tax valuation allowances, both of which can materially affect reported results without changing cash flow. Because the company has not yet generated operating revenue, quarter-to-quarter results are likely to be driven by research and development spending, clinical trial timing, and equity financing proceeds. Investors should also watch for any future accounting related to license arrangements, capitalized development assets if they arise, and potential impairment or fair value changes tied to warrants or other equity-linked instruments.

- **Stock option and warrant valuation** — Non-cash compensation and derivative-like valuation effects
- **Income tax valuation allowance** — Tax expense and balance sheet deferred tax assets
- **Clinical-stage expense timing** — Quarterly operating loss comparability
- **Equity financing accounting** — Capital structure and per-share metrics

- No operating revenue yet, so results are driven by R&D and financing
- Stock option and warrant valuation affects non-cash expense
- Income tax valuation allowance depends on future profitability assumptions
- Clinical trial spending can create uneven quarterly expense patterns
- Equity offerings and warrant exercises affect share count and capital structure
- Future license or IP accounting could become relevant if commercialization begins

---

*Last updated: 2026-08-11T04:46:24.738793+00:00*